On August 4, Hinge Health, Inc. rose 5.14% in regular trading, trading at $78.57/share, with turnover of $63.19 million. Market sentiment warmed ahead of the company's Q2 earnings report scheduled for release after market close.

Consensus estimates project Q2 revenue of $201 million, representing 60.38% year-over-year growth, with adjusted EPS expected at $0.59, up 582.69% from the prior year. The company had previously raised its Q2 revenue guidance to $200-$202 million, above analyst expectations at the time. Full-year revenue outlook was also lifted to $818-$824 million.

Additionally, a recent study published in the Journal of Comparative Effectiveness Research showed that the company's fall prevention program reduced falls by 37% and emergency department visits by 57% among adults aged 65 and older, further validating its clinical value proposition. Morgan Stanley recently raised its price target to $108 from $72, maintaining an Overweight rating, while multiple analysts maintain Buy ratings on the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)